1623P Impact of switching from BRAF/MEK inhibition to immune checkpoint inhibition before secondary resistance in metastatic melanoma: A EUMelaReg real-world study. - Weichenthal, M.; Gavrilova, I.; Mangana, J.; Leiter-Stoppke, U.; Ellebaek, E.; Ruhlmann, C.H.; Ugurel-Becker, S.; Asher, N.; Kandolf Sekulovic, L.; Gerasimov, A.; Dummer, R.; Ziogas, D.C.; et al. (Annals of Oncology, 2025)